Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

NCT07509112 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide can help adults with methamphetamine use disorder reduce their drug use.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 40 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-05 · est. completion 2027-03

Where 5 sites · Australia

What this study is testing ClinicalTrials.gov NCT07509112 ↗

Description as written by the study sponsor.

Methamphetamine use disorder is a major public health concern in Australia and globally. GLP-1 medications such as semaglutide (e.g. Ozempic) are approved for diabetes and medication, and may potentially affect craving for other substances apart from food. We do not know if this will help people who use methamphetamine ('ice') to reduce their use. This study will treat people who use methamphetamine with weekly injections of semaglutide. It will provide data on if this is a potentially safe and practical treatment for this group of people.

Treatments tested

12 weeks of weekly subcutaneous semaglutide injection Drug

12 weeks of subcutaneous semaglutide administered once weekly, starting at 0.25 mg once weekly, titrated as tolerated up to 1.0 mg over the 12-week study period.

Main thing measured	Efficacy Outcome (exploratory)
Sponsor	Kirby Institute
Conditions studied	Methamphetamine Use Disorder
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07509112 ↗